CS MEDICA A/S announces its intention to list its shares on Spotlight Stock Market

Report this content

CS MEDICA A/S (”CS MEDICA” or the ”Company”) is a Danish medico cannabis company committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids The Company hereby announces its intention to launch an initial public offering of its shares (the “IPO” or the “Offer”) and to list its shares on Spotlight Stock Market (“Spotlight”) in Q3 2021. CS MEDICA has engaged Sedermera Fondkommission to act as financial advisor, Markets & Corporate Law Nordic AB as legal advisor, Nordnet Bank AB as selling agent, and Nordic Issuing to provide issuing services in connection with the capitalization and the planned listing on Spotlight.

Motive for capitalization and listing

CS MEDICA was founded in 2011 and is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids, with a current focus on cannabidiol for the treatment of psoriasis and arthritis. CS MEDICA has an important competitive advantage, as new products introduced to the market under Medical Device Regulation (MDR) with cannabinoids must undergo the process applicable to MDR class IIa, corresponding to an application process period of two-three years. CS MEDICA will thus have a competitive advantage during this period. At present, the Company has two pioneering topicals (CBD gels) - medical device class I OTC - destined for systemic treatment of arthritis and psoriasis available. In the future, the Company also foresees great possibilities in systemic treatments, combining gels/serum and complementing it with food supplements to enhance the efficacy of the treatment.  

CS MEDICA is in the process of entering markets across the nations of Europe, with several signed distribution agreements in the United Kingdom, Netherlands, Belgium, Sweden, Germany, Austria, and Denmark (as well as negotiations with eight other countries). The Company currently has eleven products available on the European market, and an additional nine products about to be launched before the end of 2022. Until now the focus of CS MEDICA has been on expanding its operations within the Nordic countries. With a growing demand for products containing cannabinoids, CS MEDICA is preparing to scale its business with the ambition to continue organizational and product development, enter new strategic partnerships, and launch products on the larger European market.

The Board of Directors considers the IPO to be a logical step to support continued growth and strengthen CS MEDICA’s brand by providing a diversified base of shareholders and increased visibility towards potential partners and customers. As part of the Offer, the Company will carry out an issue of units to maintain the high pace of launching products, expand the scope of operations, and thus gain valuable market shares. Full terms, conditions, and instructions for the Offer will be presented in the prospectus that will be prepared by the Company in connection with the IPO, planned to be implemented during Q3 2021.

Lone Henriksen, CS MEDICA’s CEO, comments

"We are very excited about our upcoming listing on Spotlight. Collectively, the listing and forthcoming IPO will enable fast growth as we move ahead. Expanding on market activities across Europe, continued clinical studies, research, and development activities are a few of the ways we will use the issue proceeds moving forward as a public company.”

Advisors, selling agent, and issuing agency

Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic is the legal advisor to CS MEDICA in connection with the planned capitalization and listing. Nordic Issuing acts as issuing agency and Nordnet acts as selling agent.

For more information about the planned listing, please contact:
Sedermera Fondkommission
Phone: +46 (0) 40 615 14 10

Email: info@sedermera.se

For more information about CS MEDICA, please contact:

Lone Henriksen, CEO
Phone: + (45) 71 20 30 47

Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic) and CanNordic A/S (registered medical device product developer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.


Documents & Links


Cannabinoid innovation within auto-immune disorders - focusing on treatment and care for people around the world
Inspired by Nature, created by Scientists